EIF1AX Antibody

What is EIF1AX and what is its biological significance in translation initiation?

EIF1AX (eukaryotic translation initiation factor 1A, X-linked) is an essential component of the translation pre-initiation complex (PIC). It plays critical roles in protein biosynthesis by:

• Enhancing ribosome dissociation into subunits

• Stabilizing the binding of initiator Met-tRNA(I) to 40S ribosomal subunits

• Facilitating maximal rate of protein biosynthesis

The protein has an unblocked N-terminal proline consistent with the general pattern of eukaryotic proteins. Structurally, EIF1AX has important functional domains including the N-terminal tail (NTT) and C-terminal tail (CTT), which interact with other translation initiation components .

Which experimental applications are validated for EIF1AX antibodies?

EIF1AX antibodies have been validated for multiple applications with specific dilution recommendations:

*Dilution varies by specific antibody product

Note: It is recommended to titrate the antibody in each testing system to obtain optimal results, as detection sensitivity can be sample-dependent .

What are the validated protocols for detecting EIF1AX in tumor tissues?

For successful detection of EIF1AX in tumor tissues:

Immunohistochemistry protocol highlights:

• Antigen retrieval: Use TE buffer pH 9.0 (recommended) or alternatively citrate buffer pH 6.0

• Dilution range: 1:20-1:200

• Detection systems: Both DAB and fluorescent secondary antibodies have been validated

• Positive controls: Human gliomas tissue demonstrates reliable reactivity

When studying EIF1AX in cancer research, consider that expression patterns differ between cancer types. For example, in breast cancer, both nuclear and cytoplasmic staining is observed, with stronger EIF1AX staining in both compartments compared to normal mammary epithelial cells .

How can EIF1AX antibodies be used to study its role in cancer progression?

EIF1AX has emerging roles in multiple cancer types, making it an important research target:

Breast cancer:

• EIF1AX promotes breast cancer proliferation by facilitating G1/S cell cycle transition

• Mechanistically inhibits p21 transcription in a p53-independent manner

• Expression levels in breast cancer correlate with histological grades and patient survival

• Detection method: Combined qRT-PCR and IHC showed EIF1AX is significantly upregulated in carcinoma tissues compared to adjacent normal tissues

Thyroid cancer:

• EIF1AX mutations (particularly A113splice) cooperate with RAS mutations to drive thyroid tumorigenesis

• Detection of EIF1AX-c'spl variant has diagnostic significance

• EIF1AX mutants show higher affinity to components of the translation PIC and increase protein synthesis

Endometrial carcinoma:

• Cytoplasmic EIF1AX expression shows gradual increase from normal tissue through hyperplasia to carcinoma

• Nuclear EIF1AX expression follows opposite pattern

• Cytoplasmic expression correlates with histologic type, FIGO grade, stage, infiltration depth, Ki67 index, and recurrence-free survival

What methodological approaches can validate EIF1AX antibody specificity?

To ensure experimental rigor, validate antibody specificity through:

• Western blot validation:

  • Expected molecular weight: 16 kDa (calculated), but observed range of 16-23 kDa

  • Positive controls: HepG2, A375, HeLa, PC-3 cell lysates

• Genetic validation:

  • siRNA/shRNA knockdown: Validate signal reduction with EIF1AX depletion

  • Overexpression systems: Test antibody detection of tagged EIF1AX proteins

• Cross-reactivity assessment:

  • Test for cross-reactivity with Y-linked homolog

  • Evaluate specificity across species (human, mouse, rat) when performing comparative studies

How can researchers use EIF1AX antibodies to study protein-protein interactions in translation initiation?

Co-immunoprecipitation (Co-IP) studies have revealed important insights about EIF1AX interactions:

Experimental approach:

• Express HA-tagged EIF1AX (wild-type or mutants) in appropriate cell lines

• Immunoprecipitate using anti-HA antibody

• Analyze pull-down of translation initiation components by western blot

Key findings from this methodology:

• EIF1AX interacts with EIF2α, a component of the ternary complex (TC)

• EIF1AX mutants (particularly G8R, G9R, and c'spl) show increased affinity for EIF5

• These interactions suggest EIF1AX mutants result in a more stable 43S ribosomal complex

• This methodology has revealed that EIF1AX mutations can alter translation dynamics

What techniques can detect different EIF1AX subcellular localizations and their significance?

EIF1AX shows interesting subcellular localization patterns relevant to disease progression:

Methodological considerations:

• Subcellular fractionation:

  • Separate nuclear and cytoplasmic fractions before western blotting

  • Use appropriate markers (GAPDH for cytoplasm, Lamin B for nucleus)

• Immunofluorescence optimization:

  • Dilution: 1:50-1:500 (specific to antibody product)

  • Fixation: 4% paraformaldehyde recommended

  • Permeabilization: 0.1% Triton X-100

  • Include DAPI or other nuclear counterstain

• Quantification approaches:

  • Nuclear-to-cytoplasmic ratio measurement

  • Correlation with disease progression markers

Research significance:
In endometrial carcinoma, cytoplasmic EIF1AX expression increases while nuclear expression decreases during disease progression from normal tissue to carcinoma. Cytoplasmic transport appears to be regulated by exportin 1 (XPO1), and targeting this nucleocytoplasmic transport may offer therapeutic approaches .

How can I use EIF1AX antibodies to study mutant forms associated with cancer?

EIF1AX mutations cluster in two main regions:

• N-terminal tail (NTT) - first 15 amino acids (common in uveal melanoma)

• Splice acceptor site upstream of exon 6 (A113splice) - common in thyroid cancer

Methodological approaches:

• Mutation-specific antibodies: Limited commercial availability; custom antibodies may be needed

• Expression systems:

  • Transfect cells with wild-type or mutant EIF1AX constructs

  • Use antibody against tag (HA, FLAG, etc.) to detect and compare function

• Functional readouts:

  • Translation efficiency: L-azidohomoalanine (AHA) labeling of nascent proteins

  • Cell proliferation: Colony formation assays

  • Cell cycle analysis: Flow cytometry

  • Downstream targets: ATF4, c-MYC pathway activation

Research has shown that EIF1AX mutations can alter interactions with translation machinery components, particularly increasing affinity for EIF5 and stabilizing the pre-initiation complex .

What are common troubleshooting strategies for EIF1AX antibody applications?

How can I design experiments to study EIF1AX's role in regulating p21 transcription?

EIF1AX has been shown to transcriptionally repress p21 in a p53-independent manner, promoting cell cycle progression and cancer cell proliferation .

Experimental design approach:

• ChIP assays:

  • Immunoprecipitate with EIF1AX antibodies

  • Examine recruitment to p21 promoter region

  • Research has confirmed EIF1AX physically associates with the p21 promoter

• Luciferase assays:

  • Co-transfect p21 promoter-reporter construct with EIF1AX expression vectors

  • Previous studies showed EIF1AX decreased p21 gene promoter expression in a dose-dependent manner

• Rescue experiments:

  • Co-transfect EIF1AX siRNA with p21 siRNA

  • Analyze cell cycle by flow cytometry

  • Published data shows p21 downregulation in EIF1AX-downregulated cells results in decreased percentage of cells in G0/G1 phase

What control systems are essential when studying EIF1AX in cancer research?

Recommended controls for rigorous EIF1AX research:

• Cell line controls:

  • Normal cell counterparts: MCF-10A for breast cancer studies

  • Range of cancer cell lines with varying EIF1AX expression: HepG2, A375, HeLa, PC-3, HEK-293T, Jurkat cells

• Tissue controls:

  • Paired adjacent normal tissues alongside tumor samples

  • Tissue microarrays with gradient of disease progression

• Expression controls:

  • EIF1AX knockdown cells (siRNA/shRNA)

  • EIF1AX overexpression systems

  • EIF1AX mutant expression systems (particularly A113splice variants)

• Cellular compartment markers:

  • Nuclear markers: Lamin B

  • Cytoplasmic markers: GAPDH, β-actin

  • Translation machinery markers: EIF2α, EIF5

How might EIF1AX antibodies be used to develop cancer diagnostics or prognostics?

Based on current research findings, EIF1AX has potential as a diagnostic or prognostic marker:

• Breast cancer: EIF1AX expression correlates with histological grades and survival rates

• Thyroid cancer: EIF1AX mutations (particularly A113splice) strongly co-occur with RAS mutations (p=3.15×10E-13) in advanced cases

• Endometrial carcinoma: Cytoplasmic EIF1AX expression correlates with FIGO grade, stage, and recurrence-free survival

Potential development approaches:

• IHC-based scoring systems combining nuclear/cytoplasmic ratios

• Mutation-specific antibodies targeting common cancer-associated variants

• Integration with other cancer biomarkers for improved prognostic accuracy

What techniques can researchers use to study EIF1AX's role in translation regulation during stress conditions?

EIF1AX modulates translation of specific mRNAs, particularly those with regulatory elements:

Methodological approaches:

• Ribosome profiling:

  • Compare translation efficiency in cells with wild-type vs. mutant EIF1AX

  • Focus on mRNAs with complex 5'UTRs or upstream open reading frames (uORFs)

• Translation reporter assays:

  • Translation Control Reporter System (TCRS) to test ribosomal re-initiation efficiency

  • ATF4 reporter constructs with regulatory uORFs

  • Research shows EIF1AX mutants increase efficiency of ribosome re-initiation

• Stress response studies:

  • Examine EIF1AX function during integrated stress response

  • Compare WT and mutant EIF1AX effects on stress granule formation

  • Study ATF4 and CHOP induction as markers of stress response activation

Understanding these mechanisms could reveal how EIF1AX mutations contribute to cancer cell survival under stress conditions, potentially identifying therapeutic vulnerabilities.